Arrowhead Pharmaceuticals Inc.

ARWR | NASDAQ

Price Alert Chart Builder DCF Calculator

$68.79

+$2.31 (+3.47%)

At close: Sep 21, 2026, 4:00 PM ET

$69.52

+$0.73 (+1.06%)

Pre-market: Sep 22, 2026, 5:18 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+3.47%

(1D)

Rating

Updated: Aug 25, 2026

50.9

Fundamentals Average

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $9.69B

1D Range

66.06 69.19

52W Range

30.71 95.49

Valuation (TTM)

PE -30.71

PB 20.81

EV/EBITDA -63.79

Valuation (NTM)

Forward PE N/A

Forward PEG -0.95

Price Target $104.43

Cash Flow

FCF Yield -0.8%

SBC Adj. FCF Yield -1.5%

SBC Impact -93.2%

Margins

Gross Margin 100.0%

Operating Margin -33.8%

FCF Margin -11.2%

Growth (CAGR)

Revenue 3Y | 5Y 37.7% | 44.1%

Dil EPS 3Y | 5Y 44.3% | -5.0%

FCF 3Y | 5Y 109.7% | 19.0%

Returns

ROA -15.2%

ROE -60.5%

ROIC -12.1%

Financial Health

Net Cash

$737.89M

Current Ratio 5.90

Interest Coverage -2.45

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challeng...

Sector Healthcare

Industry Biotechnology

Employees 711

IPO Date Dec 15, 1993

Website arrowheadpharma.com

Fiscal Year October - September

Full Company Profile

Latest News

3 days ago · marketbeat.com

Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands

Arrowhead Pharmaceuticals NASDAQ: ARWR is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline programs targeting cardiometabolic disease, obesity and central nervous system disorders.

5 days ago · seekingalpha.com

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

6 days ago · seekingalpha.com

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

7 days ago · businesswire.com

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC.

12 days ago · seekingalpha.com

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

16 days ago · fool.com

Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million

The transaction was valued at $1 million. The sale reduced the director's direct equity holdings by 9%.

22 days ago · seekingalpha.com

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript

22 days ago · marketbeat.com

Arrowhead's Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials

Arrowhead Pharmaceuticals NASDAQ: ARWR presented 12-month results from its Phase 3 SHASTA-3 and SHASTA-4 trials evaluating plozasiran in adults with severe hypertriglyceridemia, reporting substantial reductions in triglycerides and acute pancreatitis events versus placebo. The company said the data were presented at the European Society of Cardiology Congress in Munich and have been accepted for publication in a major medical journal.

29 days ago · businesswire.com

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present important new data at the European Society of Cardiology Congress (ESC) in Munich, Germany. ESC 2026 Presentation Details Date & Time: Sunday, August 30, 2026, 17:30 CEST Session Title: HOT LINE 9 Late-breaking Science Session Location: Munich Auditorium-Hall B3 Title: Plozasiran in patients with severe hypertriglyceridemia: the SHASTA-3 and SHASTA-4 pivotal trial 12-month.